A team led by researchers from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute has discovered a promising new approach to treating advanced colorectal cancer. The study, published in Nature, identifies a key marker of particularly aggressive and treatment-resistant colorectal cancer cells. At the same time, the researchers demonstrate using mini-tumors and mouse models that already approved drugs targeting this marker can specifically attack the metastasis-initiating cells and, when combined with standard therapies, significantly improve their effectiveness.

Researchers at VIB and KU Leuven, with international partners, have uncovered how fatty liver disease can fuel the most aggressive form of metastatic colorectal cancer. The findings, which appear in the leading journal Nature, not only explain why some patients face dramatically poorer outcomes but also highlight how metabolic conditions such as fatty liver disease may directly influence cancer progression, paving the way for more precise therapies tailored to a patient’s metabolic health.

T cells are an elite fighting force of the immune system, seeking out and destroying diseased cells. But in a prolonged campaign against a chronic condition — like a viral infection, or cancer — the body needs a steady supply of these killer troops. Where and how these killer troops are generated has been a mystery.

A new UCLA-led study found removing the cancer label could dramatically reduce overtreatment and encourage more men to get screened, potentially leading to significantly fewer deaths from aggressive prostate cancer.

The identification of new molecular markers for multiple myeloma paves the way for more precise therapies

A team of researchers from Cima Universidad de Navarra has revealed the essential role of the IRF2 transcription factor in the development of this type of hematologic cancer. This finding will help drive new therapeutic strategies that will improve treatment for patients with this disease

Dobutamine is a well-known drug given intravenously to patients in acute heart failure, where it stimulates the heart to pump more effectively. Over the past decade, however, a growing body of research has reported something surprising: the drug also suppresses the growth of cancer cells in bone tumours (osteosarcoma), stomach cancer, and multiple myeloma. No one could fully explain why. A research team led by Dr. Safa Daoud, from the Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan, and co-led by Dr. Mutasem O. Taha from the Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, noticed a telling pattern in the scientific literature: all the cancers where dobutamine shows activity also tend to produce unusually high levels of a protein called ROCK2 — a molecular switch that, when left unchecked, pushes tumour cells to grow, spread, and resist treatment. The team's central question was whether dobutamine's anticancer effects could be explained, at least in part, by its ability to block ROCK2 directly.